B-Cell Lymphomas

  • Rita M. Braziel
  • Guang Fan


The B-cell lymphomas (BCLs) represent 80% to 90% of non-Hodgkin lymphomas in the Western world and include multiple lymphoma subtypes with different biologies, natural histories, morphologic characteristics, immunophenotypes, genetic features, prognoses, and responses to therapy.1 Numerous subtypes of B-cell malignancies are defined according to the World Health Organization (WHO) classification (Table 32-1). Accurate subclassification of these BCLs has always been a challenge for pathologists, resulting in early application of new techniques in genetic analysis to these tumors to improve diagnostic accuracy. Today, the genetic features of BCLs are used not only to aid in rendering an accurate primary diagnosis, but also to predict prognosis, to assess for minimal residual disease after therapy, and even to help determine optimal therapy.


Southern Blot Analysis Follicular Lymphoma Minimal Residual Disease Mantle Cell Lymphoma Splenic Marginal Zone Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (World Health Organization Classification of Tumors). Lyon, France: IARC Press; 2001.Google Scholar
  2. 2.
    Arber DA. Molecular diagnostic approach to non-Hodgkin’s lymphoma. J Mol Diagn. 2000;2:178–190.PubMedGoogle Scholar
  3. 3.
    Pan L, Cesarman E, Knowles DM. Antigen receptor genes: structure, function, and genetic analysis of their rearrangements. In: Knowles D, ed. Neoplastic Hematopathology, 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2001:307–328.Google Scholar
  4. 4.
    Korsmeyer SJ, Hieter PA, Ravetch JV, et al. Developmental hierarchy of immunoglobulin gene rearrangement in human leukemic pre-B-cells. Proc Natl Acad Sci U S A. 1981;78:7096–7100.PubMedCrossRefGoogle Scholar
  5. 5.
    Lin D, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404–1409.PubMedCrossRefGoogle Scholar
  6. 6.
    Krober A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416.PubMedGoogle Scholar
  7. 7.
    Rosenwald A, Alizadeh AA, Widhopt F, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647.PubMedCrossRefGoogle Scholar
  8. 8.
    Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–15529.PubMedCrossRefGoogle Scholar
  9. 9.
    Idia S, Rao PH, Nallasivam P, et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996;88:4110–4117.Google Scholar
  10. 10.
    Baens M, Maes B, Steyls A, et al. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol. 2000;156:1433–1439.PubMedGoogle Scholar
  11. 11.
    Remstein ED, James CD, Kurtin. Incidence and subtype specificity of API2-MALT1 fusion translocation in extranodal, nodal, and splenic marginal zone lymphoma. Am J Pathol. 2000;156:1183–1188.PubMedGoogle Scholar
  12. 12.
    Ye H, Leu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101:2547–2550.PubMedCrossRefGoogle Scholar
  13. 13.
    Liu H, Ye H, Dogan A, et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001;98:1182–1187.PubMedCrossRefGoogle Scholar
  14. 14.
    Okabe M, Inagaki H, Ohshima, et al. API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Am J Pathol. 2003;162:1113–1122.PubMedGoogle Scholar
  15. 15.
    Zhang Q, Sieber R, Yan M, et al. Inactivation mutations and overexpression of BCL10, a caspase recruitment domain-containing gene in MALT lymphoma with t(1;14)(p22;q32). Nat Genet. 1999;22:63–68.PubMedCrossRefGoogle Scholar
  16. 16.
    Streubel B, Lamprecht A, Dierlamm J, et al. t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–2339.PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang F, Lin F, Price R, et al. Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes. J Mol Diagn. 2002;4:144–149.PubMedGoogle Scholar
  18. 18.
    Albinger-Hagyi A, Hochreutener B, Abdou MT, et al. High frequency of t(14;18) translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol. 2002;160:823–832.Google Scholar
  19. 19.
    Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain-reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone-marrow transplantation for B-cell lymphoma. Blood. 1993;81:3449–3457.PubMedGoogle Scholar
  20. 20.
    Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000;11(suppl 1):137–140.PubMedCrossRefGoogle Scholar
  21. 21.
    Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000;64:190–196.PubMedCrossRefGoogle Scholar
  22. 22.
    Belaud-Rotureau MA, Parrens M, Dubus P, et al. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15:517–525.PubMedCrossRefGoogle Scholar
  23. 23.
    Hui P, Howe JG, Crouch J, et al. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry. Leuk Lymphoma. 2003;44:1385–1394.PubMedCrossRefGoogle Scholar
  24. 24.
    Barrans SL, O’Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117:322–332.PubMedCrossRefGoogle Scholar
  25. 25.
    Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945–951.PubMedCrossRefGoogle Scholar
  26. 26.
    Barrans SL, Evans PA, O’Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9:2133–2139.PubMedGoogle Scholar
  27. 27.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.PubMedCrossRefGoogle Scholar
  28. 28.
    Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.PubMedCrossRefGoogle Scholar
  30. 30.
    Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1988;85:2748–2752.PubMedCrossRefGoogle Scholar
  31. 31.
    Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804–812.PubMedGoogle Scholar
  32. 32.
    Bellan C, Lazzi S, De Falco G, et al. Burkitt’s lymphoma. New insights into molecular pathogenesis. J Clin Pathol. 2003;56:188–192.PubMedCrossRefGoogle Scholar
  33. 33.
    Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97:3713–3720.PubMedCrossRefGoogle Scholar
  34. 34.
    Moreau P, Facon T, Leieu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–1583.PubMedCrossRefGoogle Scholar
  35. 35.
    Eckert C, Landt O, Seeger K, et al. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:316–323.PubMedCrossRefGoogle Scholar
  36. 36.
    Szczepanski T, Willemse MJ, Brinkhof B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315–2323.PubMedCrossRefGoogle Scholar
  37. 37.
    Gabert J, Beillard E, van der Veldon VHJ, et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer Program. Leukemia. 2003:1–40Google Scholar
  38. 38.
    O’Leary TJ, Brindza L, Kant JA, et al. Immunoglobulin and T-Cell Receptor Gene Rearrangement Assays: Approved Guidelines. National Committee for Clinical Laboratory Standards (NCCLS). Vol 15. 1995:1–30.Google Scholar
  39. 39.
    Bagg A, Braziel RM, Arber DA, et al. Immunoglobulin heavy chain gene analysis in lymphoma: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J Mol Diagn. 2002;4:81–89.PubMedGoogle Scholar
  40. 40.
    Elenitoba-Johnson KSJ, Bohling SE, Mitchell RS, et al. PCR analysis of the immunoglobulin heavy chain gene in polyclonal processes can yield pseudoclonal bands as an artifact of low B cell number. J Mol Diagn. 2000;2:92–96.PubMedGoogle Scholar
  41. 41.
    Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin. J Mol Diagn. 2002;2:5–10.CrossRefGoogle Scholar
  42. 42.
    Lee SC, Berg KD, Racke FK, et al. Pseudo-spikes are common in histologically benign lymphoid tissues. J Mol Diagn. 2000;2:145–152.PubMedGoogle Scholar
  43. 43.
    Summers KE, Goff LK, Wilson AG, et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol. 2001;19:420–424.PubMedGoogle Scholar
  44. 44.
    Limpens J, De Jong D, van Krieken JHJM, et al. Bcl-2/JH rearrangements in benign lymphoid tissue with follicular hyperplasia. Oncogene. 1991;6:2271–2276.PubMedGoogle Scholar
  45. 45.
    Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells in normal individuals. Blood. 1995;85:2528–2536.PubMedGoogle Scholar
  46. 46.
    Van der Velden VHJ, Willemse JM, van der Schoot CE, et al. Immunoglobulin kappa deleting element rearrangements in precursor B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia. 2002;16:928–936.PubMedCrossRefGoogle Scholar
  47. 47.
    Hsi ED, Tubbs RR, Lovell, et al. Detection of bcl-2/JH translocation by polymerase chain reaction: a summary of the experience of the molecular oncology survey of the College of American Pathologists. Arch Pathol Lab Med. 2002;126:902–908.PubMedGoogle Scholar
  48. 48.
    Johnson PWM, Swinbank K, MacLennan S, et al. Variability of polymerase chain reaction detection of the bcl-2-IGH translocation in an international multicentre study. Ann Oncol. 1999;10:1349–1354.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Rita M. Braziel
    • 1
  • Guang Fan
    • 2
  1. 1.Hematopathology, Department of PathologyOregon Health and Sciences UniversityPortlandUSA
  2. 2.Department of PathologyOregon Health and Sciences UniversityPortlandUSA

Personalised recommendations